summary: Researchers are testing a new brain-computer interface (BCI) that has the potential to transform neurosurgery and patient care. The Layer 7 cortical interface boasts 1,024 electrodes for unparalleled brain activity mapping, promising new insights into neurological and psychiatric conditions. This flexible, ultra-thin device is designed to minimize tissue damage and represents a significant advancement in BCI technology. This research aims to utilize this detailed data to investigate the effects on brain function and disease, and discover new treatments.
Important facts:
- Innovative design: The layer 7 cortical interface features 1,024 electrodes on a flexible film and provides high-resolution mapping of brain activity.
- Interdisciplinary research: A multidisciplinary team at Mount Sinai is analyzing data from this interface to understand brain-behavior relationships and the impact of disease.
- Clinical potential: This BCI could significantly improve our understanding of neurological conditions and lead to new therapeutic approaches.
sauce: Mount Sinai Hospital
For the first time in New York, an interdisciplinary team of neurosurgeons and neuroscientists at the Icahn School of Medicine at Mount Sinai are researching a new brain-computer interface designed to map large areas of the brain's surface in real time at hundreds of resolutions. There is. It is many times more detailed than typical arrays used in neurosurgery.
A brain computer interface (BCI) is a system that decodes brain signals and translates them into commands for external technology. The ultimate goal of BCI is to restore function to debilitated patients by allowing them to operate digital devices using just their thoughts.
The Layer 7 Cortical Interface, developed by Precision Neuroscience Corporation, contains 1,024 tiny electrodes spanning an area of 1.5 square centimeters and is embedded in a flexible film that conforms to the surface of the brain. The film is one-fifth as thick as a human hair and is designed to be implanted and removed by neurosurgeons without damaging brain tissue.
“Mount Sinai has the ability to conduct cutting-edge biomedical and scientific research, a commitment to excellence in patient care, and an entrepreneurial drive to generate new treatments and advances in care,” said Joshua B. Bederson. We have established an international reputation for our approach.” M.D., Chief of Neurosurgery at Mount Sinai Health System and Co-Founder of Mount Sinai Biodesign.
“This culture of excellence, innovation, and collaboration attracts the world's brightest clinicians and researchers who can rapidly translate research breakthroughs into new products and services that deliver meaningful benefits to patients and society. Masu.
“We are proud to be one of the leading facilities participating in the trials of the new array and look forward to seeing what we learn from the detailed information we will collect and analyze.”
As part of an open-label, single-arm feasibility study, Mount Sinai neurosurgeons temporarily placed a research device on the surface of study participants' brains during an intracranial procedure, where surface mapping It is routinely performed and correlated (tests that measure) with evoked potentials. the brain's response to sensory stimuli), or standardized behavioral tasks routinely performed as part of these procedures.
The device records high-resolution electrophysiological signals, and the data collected is compared to data obtained using standard-of-care cortical surface arrays.
A team of Mount Sinai neuroscientists with deep expertise in human electrophysiology will analyze and interpret the large amount of data collected from this device.
A secondary objective of the study is to evaluate the ability of thin-film electrodes to map electrophysiological correlates of awake behavioral tasks, including motor, language, and cognitive tasks.
“Despite the great complexity of activity across the human brain, standard monitoring tools can capture only a small fraction of the data needed, either from a small number of regions or with very slow temporal resolution.
“This low-resolution data significantly limits our understanding of brain function and brain disorders,” said Dr. Icahn, associate professor of neuroscience and neurosurgery and director of the Human Neurophysiology Laboratory, and director of the Icahn Mt. said Dr. Ignacio Saez, who is also the principal investigator on the Sinai trial.
“This new device is exciting because it collects thousands of data points per second from 1,000 brain regions in each participant, giving us a highly detailed picture of electrical activity in the brain.
“By monitoring neural activity at this unprecedented resolution, the multidisciplinary team at Mount Sinai has gained important insights into how brain function supports behavior and is influenced by disease states. I would like to.
“Our ultimate goal is to gain practical knowledge that opens the door to new treatments for neurological and psychiatric diseases and improves the quality of life for patients.”
Precision Neuroscience was co-founded by Benjamin Rapoport, MD, assistant professor of neurosurgery at Icahn Mount Sinai and a practicing neurosurgeon with PhDs in electrical engineering and computer science.
Dr. Rapoport also serves as scientific director of Mount Sinai Biodesign, a medical technology prototyping center and incubator within the Mount Sinai Health System.
Dr. Rapoport is an equity owner of Precision Neuroscience and serves as the company's Chief Scientific Officer and a member of the Board of Directors. As a faculty member in the Department of Neurosurgery, he reports directly to Dr. Bederson.
Neither Dr. Bederson nor Mount Sinai has a financial interest in Precision Neuroscience. All precision neuroscience research at Mount Sinai is conducted by independent researchers with no financial ties to the company.
About this neurotechnology and BCI research news
author: elizabeth dowling
sauce: Mount Sinai Hospital
contact: Elizabeth Dowling – Mount Sinai Hospital
image: Image credited to Neuroscience News
